



Supplementary Figure 1. CD4⁺ and CD4⁺ depleted peptide-specific T cell immune responses. Following co-culture with A2⁺/high HCC1500 breast cancer cells, P11- and P73-primed T cells were fractionated into 2 subpopulations, a CD4⁺ and CD4⁺depleted T cell subset, for IFN- γ ELISpot analysis. Representative IFN- γ ELISpot images are given for one donor, while Tukey box plots represent data of two donors. * $p < 0.05$, *** $p < 0.001$.



Supplementary Figure 2. Immunogenicity of P11- and P73- specific T cells against loss-of-function LDHC BT549 breast cell line model. **a**, LDHC expression of shCTR (A2+/high) and shLDHC (A2+/low) BT549 cells, determined by qRT-PCR, western blot and flow cytometry. **b**, IFN- γ release and **c**, cytolytic activity of PP2-, PP8- and P11- and P73-specific T cells in co-culture with A2+/high and A2+/low BT549 cells. Representative IFN- γ ELISpot images are given for one donor, while Tukey box plots represent data of two donors. MFI, mean fluorescence intensity. * $p < 0.05$, ** $p < 0.01$, *** $p < 0.001$.



Supplementary Figure 3. HLA-A*02 specificity of P11- and P73-induced T cell responses. LDHC peptide loaded-T2 cells were incubated with their respective primed T cells followed by measurement of IFN- γ release. T2 cells were loaded with either P11, P73 or no peptide (control) in addition to a non-reactive peptide (P78). Representative IFN- γ ELISpot images are given for one donor, while Tukey box plots represent data of two donors. . * $p < 0.05$, ** $p < 0.01$.